Zhejiang Starry Pharmaceutical Company Description

Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally.

Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products, such as levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate.

The company was founded in 1997 and is headquartered in Taizhou, China.

Zhejiang Starry Pharmaceutical Co.,Ltd.

Country	China
Founded	1997
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	1,754
CEO	Weiyi Shen

Contact Details

Address: Modern Industrial Cluster Area Taizhou, 317306 China
Phone	86 576 8771 8605
Website	starrypharm.com

Stock Details

Ticker Symbol	603520
Exchange	Shanghai Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE1000026N8
SIC Code	2833

Key Executives

Name	Position
Weiyi Shen	Vice Chairman and GM
Junfeng Guo	Financial Director
Chao Sun	Board Secretary
Chaoyang Yao	Deputy General Manager
Chun Ye	Deputy General Manager
Haiyasheng Li	Accounting Supervisor